MET and non-small cell lung carcinoma: In recent years, the FDA has granted approval for small molecule inhibitors, including capmatinib, savolitinib, and tepotinib, for the treatment of patients with metastatic NSCLC who possess MET exon 14 skipping mutations (Wu and Lin, 2022).